Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0568

-11.3%

11:32 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Howard Williams who wrote (12760)	4/3/2014 1:11:12 PM
From: Mark Buczynski	of 13111

From a poster on another board... BioCentury Reports News of Provectus' Request for Breakthrough Therapy Designation for PV-10 for Melanoma Thursday April 3, 2014 The Clinical News section of the March 31, 2014 edition of BioCentury covered news of Provectus' recent submission of a request to the US FDA to grant Breakthrough Therapy Designation to PV-10 for the treatment of locally advanced cutaneous melanoma. The article is available at www.pvct.com//news/BioCentury-PVCT-03-31-2014.pdf on the Provectus website.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next